home / stock / sphs / sphs news

SPHS News and Press, Sophiris Bio Inc From 08/27/19

Stock Information
Company Name: Sophiris Bio Inc
Stock Symbol: SPHS
Market: OTC
Website: sophirisbio.com
Menu
SPHS SPHS Quote SPHS Short SPHS News SPHS Articles SPHS Message Board
Get SPHS Alerts

News, Short Squeeze, Breakout and More Instantly...
SPHS - Sophiris Bio Announces $4.0 Million Registered Direct Offering

SAN DIEGO and VANCOUVER, British Columbia , Aug. 27, 2019 /PRNewswire/ -- Sophiris Bio Inc. (Nasdaq: SPHS) (the "Company" or "Sophiris"), a biopharmaceutical company studying topsalysin (PRX302), a first-in-class, pore-forming protein, in late-stage clinical trials for the treatment of ...
SPHS - Sophiris Bio EPS beats by $0.04

Sophiris Bio (NASDAQ: SPHS ): Q2 GAAP EPS of -$0.07 beats by $0.04 . More news on: Sophiris Bio, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

SPHS - Sophiris Bio Reports Second Quarter 2019 Financial Results and Recent Corporate Highlights

SAN DIEGO and VANCOUVER, British Columbia , Aug. 9, 2019 /PRNewswire/ -- Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"), a biopharmaceutical company studying topsalysin (PRX302), a first-in-class, pore-forming protein, in late-stage clinical trials for the treatment...

SPHS - Sophiris Bio Receives Positive Feedback from European Medicines Agency Regarding Phase 3 Localized Prostate Cancer Clinical Trial Design

SAN DIEGO and VANCOUVER, British Columbia , June 19, 2019 /PRNewswire/ -- Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"), a biopharmaceutical company studying topsalysin (PRX302), a first-in-class, pore-forming protein, in late-stage clinical trials for the tre...
SPHS - Sophiris Bio beats by $0.02

Sophiris Bio (NASDAQ: SPHS ): Q1 GAAP EPS of -$0.08  beats by $0.02 . More news on: Sophiris Bio, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

SPHS - Sophiris Bio Reports First Quarter 2019 Financial Results

SAN DIEGO and VANCOUVER, British Columbia , May 9, 2019 /PRNewswire/ -- Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company," "We" or "Sophiris"), a biopharmaceutical company developing topsalysin (PRX302), a first-in-class, pore-forming protein, in late-stage clinical trials for the tr...

SPHS - Sophiris Bio (SPHS) Presents At H.C. Wainwright & Co. Annual Global Life Sciences Conference - Slideshow

The following slide deck was published by Sophiris Bio, Inc. in conjunction with this Read more ...

SPHS - Sophiris Bio to Present at Two Upcoming Investor Conferences

SAN DIEGO and VANCOUVER, British Columbia , April 2, 2019 /PRNewswire/ -- Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"), a biopharmaceutical company studying topsalysin (PRX302), a first-in-class, pore-forming protein, in late-stage clinical trials for th...

SPHS - Sophiris Bio reports Q4 results

Sophiris Bio (NASDAQ: SPHS ): Q4 GAAP EPS of $0.18. More news on: Sophiris Bio, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

SPHS - Sophiris Bio Reports Fourth Quarter 2018 and Year-end Financial Results and Recent Corporate Highlights

SAN DIEGO and VANCOUVER, British Columbia , March 13, 2019 /PRNewswire/ -- Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company," "We" or "Sophiris"), a biopharmaceutical company developing topsalysin (PRX302), a first-in-class, pore-forming protein, in late-stage clinical trials for the trea...
Previous 10 Next 10